Lanuti Michael, Sharma Amita, Digumarthy Subba R, Wright Cameron D, Donahue Dean M, Wain John C, Mathisen Douglas J, Shepard Jo-Anne O
Division of Thoracic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
J Thorac Cardiovasc Surg. 2009 Jan;137(1):160-6. doi: 10.1016/j.jtcvs.2008.08.034. Epub 2008 Oct 30.
This study evaluated long-term results of radiofrequency ablation for medically inoperable early-stage lung cancer.
Thirty-one consecutive patients with biopsy-proven non-small cell lung cancer underwent 38 treatments of computed tomographically guided radiofrequency ablation in a 4.5-year period. All patients were carefully selected and deemed medically ineligible for resection by a multidisciplinary team. Radiofrequency ablation was performed with curative intent with a single or cluster cool-tip electrode. Patients were hospitalized for 23-hour observation.
Treatment was complete in all cases, with no 30-day mortality. Local recurrence was confirmed radiographically by computed tomography, positron emission tomography, or both after 31.5% of treatments (12/38). Two patients were successfully retreated for technical failures related to pneumothorax; 3 underwent radiotherapy with stable disease. Mean maximal diameter of 38 tumors treated was 2.0 +/- 1.0 cm (range 0.8-4.4 cm). After median follow-up of 17 +/- 11 months, 74% of patients (23/31) were alive. Three patients died of metastatic disease; 5 died of pneumonia remote from treatment. The 2- and 4-year survivals were 78% and 47%, respectively. Median overall survival was 30 months. Pneumothorax (13%), pneumonia (16%), and pleural effusion (21%), were the most common complications.
Radiofrequency ablation of medically inoperable early-stage lung cancer in carefully selected patients yields encouraging midterm results without significant loss of pulmonary function. Local tumor progression appears related to lung tumors larger than 3 cm. Computed tomography and positron emission tomography need further validation for the early identification of local tumor progression following radiofrequency ablation.
本研究评估了射频消融治疗医学上无法手术的早期肺癌的长期效果。
在4.5年期间,31例经活检证实为非小细胞肺癌的患者接受了38次计算机断层扫描引导下的射频消融治疗。所有患者均经过精心挑选,多学科团队认为其在医学上不适合进行手术切除。采用单电极或集束冷循环电极进行有治愈意图的射频消融治疗。患者住院观察23小时。
所有病例治疗均完成,无30天死亡率。31.5%(12/38)的治疗后,通过计算机断层扫描、正电子发射断层扫描或两者进行影像学检查确认局部复发。2例患者因与气胸相关的技术失败而成功接受再次治疗;3例患者接受放射治疗,病情稳定。接受治疗的38个肿瘤的平均最大直径为2.0±1.0 cm(范围0.8 - 4.4 cm)。中位随访17±11个月后,74%(23/31)的患者存活。3例患者死于转移性疾病;5例患者死于与治疗无关的肺炎。2年和4年生存率分别为78%和47%。中位总生存期为30个月。气胸(13%)、肺炎(16%)和胸腔积液(21%)是最常见的并发症。
在精心挑选的患者中,对医学上无法手术的早期肺癌进行射频消融可取得令人鼓舞的中期结果,且肺功能无明显丧失。局部肿瘤进展似乎与大于3 cm的肺部肿瘤有关。计算机断层扫描和正电子发射断层扫描在早期识别射频消融后局部肿瘤进展方面需要进一步验证。